42 Current news of Qiagen

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

QIAGEN launches coronavirus test kit in Germany following derogation by BfArM

19-Mar-2020

QIAGEN announced that it has obtained derogation in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2. At the same time, the ...

more

QIAGEN dramatically ramping up global production capacity for RNA extraction kits for use in detection of SARS-CoV-2 coronavirus

18-Mar-2020

QIAGEN announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19. QIAGEN has historically allocated global production capacity to ...

more

image description
Thermo Fisher Scientific to Acquire QIAGEN

03-Mar-2020

Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the ...

more

image description
QIAGEN announces CEO leadership transition

Peer M. Schatz to step down as CEO

08-Oct-2019

QIAGEN N.V. announced thatPeer M. Schatz, Chief Executive Officer, has notified the Company that, after 27 years at QIAGEN, he has decided to step down as Chief Executive Officer and Chairman of the Management Board. He will remain with QIAGEN as Special Advisor to the Supervisory Board and ...

more

QIAGEN acquires Spanish diagnostics start-up company

QIAGEN enters into agreement to acquire STAT-Dx

09-Feb-2018

QIAGEN N.V. announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven ...

more

QIAGEN joins CANCER-ID consortium for liquid biopsy workflows

Public-private partnership aims to standardize and clinically validate blood-based biomarkers

31-Mar-2017

QIAGEN N.V. announced it has joined CANCER-ID, a public-private consortium aiming to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer. Rapid advances in the use of liquid biopsies, which enable cancer treatment and monitoring through the ...

more

QIAGEN partners with sequencing provider

06-May-2015

QIAGEN N.V. announced that it has expanded its relationship with BG to provide QIAGEN’s Ingenuity® Variant Analysis™ in integrated bioinformatics for all customers of BGI’s sequencing services.Under the reseller agreement, BGI customers will receive sequencing data generated from their samples ...

more

QIAGEN acquires Enzymatics enzyme solutions unit

13-Jan-2015

QIAGEN N.V. announced the acquisition of the Enzyme Solutions Unit of Enzymatics, a world leader in the development, manufacturing, and OEM supply of enzymes essential to driving the adoption of Next-Generation Sequencing (NGS) and other genetic analysis technologies in life sciences research and ...

more

QIAGEN announces broad agreement with Astellas Pharma to develop companion diagnostics

First two programs aim to create tests to aid in cancer treatment with Astellas compounds under development

30-Oct-2014

QIAGEN N.V. announced a master collaboration agreement with Astellas Pharma Inc. to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases. The scope of the agreement is not restricted to certain sample types, platforms, indications or ...

more

QIAGEN adds promising genomic biomarkers to pipeline

Mutations of SF3B1 gene indicate favorable prognosis for patients with bone marrow disorders

30-Jul-2014

QIAGEN N.V. announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo. SF3B1 is believed to play a critical role in the prognosis of patients with myelodysplastic syndromes (MDS), a group of hematological cancers in which bone marrow does not ...

more

Page 1 From 5
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE